ProShares Ultra NASDAQ Biotechnology
32 hedge funds and large institutions have $54.6M invested in ProShares Ultra NASDAQ Biotechnology in 2021 Q3 according to their latest regulatory filings, with 5 funds opening new positions, 8 increasing their positions, 6 reducing their positions, and 9 closing their positions.
201% more capital invested
Capital invested by funds: $18.2M → $54.6M (+$36.5M)
33% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 6
12.74% more ownership
Funds ownership: 6.7% → 19.44% (+13%)
5% more call options, than puts
Call options by funds: $8.41M | Put options by funds: $8.01M
11% less funds holding
Funds holding: 36 → 32 (-4)
44% less first-time investments, than exits
New positions opened: 5 | Existing positions closed: 9
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HCM
Howard Capital Management
Roswell,
Georgia
|
+$21.2M |
| 2 |
GWM
Geneos Wealth Management
Englewood,
Colorado
|
+$20.5M |
| 3 |
OMC
Old Mission Capital
Chicago,
Illinois
|
+$2.19M |
| 4 |
OPS
Orion Portfolio Solutions
Omaha,
Nebraska
|
+$1.39M |
| 5 |
TFA
Toth Financial Advisory
Leesburg,
Virginia
|
+$584K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$1.3M |
| 2 |
HF
HRT Financial
New York
|
-$1.18M |
| 3 |
Jane Street
New York
|
-$1.09M |
| 4 |
TRCT
Tower Research Capital (TRC)
New York
|
-$687K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$276K |
BIB Hedge Fund Activity: Q3 2021 in Review
32 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q3 2021, worth a combined $54.6M — up 201% from $18.2M a quarter earlier.
Sellers outnumbered buyers: 9 funds closed out of BIB and 5 opened new positions — a net loss of 4 holders — while 6 trimmed existing stakes and 8 added.
The largest buyer was Howard Capital Management, opening a new position worth an estimated $21.2M. The largest seller was Citadel Advisors, cutting an estimated $1.3M.
- 32 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q3 2021, down from 36 in Q2 2021.
- Funds reported $54.6M of ProShares Ultra NASDAQ Biotechnology stock for Q3 2021, up 201% quarter-over-quarter.
- 5 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q3 2021 and 9 closed out, a net change of -4 holders.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q3 2021 was Howard Capital Management, an estimated $21.2M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q3 2021 was Citadel Advisors, an estimated $1.3M sold.
Based on aggregated 13F filings for Q3 2021.